US MOVERS&SHAKERS Sep 09-Sep 13, 2024
AstraZeneca, Daiichi Sankyo Reports Safety Profile of Breast Cancer Drug in Phase 3b/4 Study
AstraZeneca Chair Shows Confidence With Share Purchase
AstraZeneca, Roche Cut at Deutsche After Trial Readouts for Key Drugs
Express News | AstraZeneca And Daiichi Sankyo To Present Findings Of ENHERTU Showing Clinical Activity In Patients With HER2 Positive Metastatic Breast Cancer And Brain Metastases
ENHERTU (Fam-trastuzumab Deruxtecan-nxki) Showed Substantial Clinical Activity in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastases
AstraZeneca Stock Downgraded on Drug Trial Results
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
AstraZeneca's Cancer Drug Trial Data Raises New Regulatory Concerns -- Market Talk
'Moffitt Cancer Center Announces Strategic Collaboration With AstraZeneca To Accelerate Oncology Cell Therapies'
Today's Morning Movers and Top Ratings | ADBE, ORCL, MRNA and More
AstraZeneca Cut to Sell From Hold by Deutsche Bank
AstraZeneca Target Cut to 10500p From 11000p by Deutsche Bank
Enhertu Showed Substantial Clinical Activity in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastases
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Kepler Capital Sticks to Their Hold Rating for AstraZeneca (AZN)
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $89
AstraZeneca Analyst Ratings
AlphaValue/Baader Europe Upgrades AstraZeneca to Add, Lifts PT
Nordea Bank Downgrades AstraZeneca to Sell